EP0557307A1 - Verfahren zur herstellung von 4,5,6,7-tetrahydro-imidazo-(4,5,ljk) (1,4)-benzodiazepin-2-(1h)-thionen sowie zwischenprodukte - Google Patents

Verfahren zur herstellung von 4,5,6,7-tetrahydro-imidazo-(4,5,ljk) (1,4)-benzodiazepin-2-(1h)-thionen sowie zwischenprodukte

Info

Publication number
EP0557307A1
EP0557307A1 EP91918424A EP91918424A EP0557307A1 EP 0557307 A1 EP0557307 A1 EP 0557307A1 EP 91918424 A EP91918424 A EP 91918424A EP 91918424 A EP91918424 A EP 91918424A EP 0557307 A1 EP0557307 A1 EP 0557307A1
Authority
EP
European Patent Office
Prior art keywords
formula
hydrogen
compound
radical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91918424A
Other languages
German (de)
English (en)
French (fr)
Inventor
Herbert Leinert
Alfred Mertens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH, Boehringer Mannheim GmbH filed Critical Roche Diagnostics GmbH
Publication of EP0557307A1 publication Critical patent/EP0557307A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups

Definitions

  • the invention relates to 2- [(3-nitro-benzyl) amino] alkyl-a ine and a process for the preparation of 4,5,6,7-tetra-hydro-imidazo- [4,5, ljk] [1.4] -benzodiazepin-2 (IH) thiones via the 2- [(3-nitro-benzyl) amino] alkylamines as intermediates.
  • the invention relates to an improved process for the preparation of 4,5,6,7-tetrahydro-imidazo- [4,5, ljk] [1.4] - benzodiazepine-2 (IH) thiones of the general formula I
  • R1 is a hydrogen atom or a straight-chain or branched alkyl radical having 1-6 carbon atoms
  • R2 represents a hydrogen atom, a straight-chain or branched alkyl radical having 1-6 carbon atoms, a straight-chain or branched alkenyl radical having 3-6 carbon atoms, a C 3 -C 6 alkynyl radical, a C 3 -C 5 cycloalkyl radical or a C ⁇ _-Cg- Alkyl radical which can also be substituted by a phenyl radical or a C3-Cg-cycloalkyl radical, 3 and R4 are identical or different and, independently of one another, denote hydrogen, halogen, hydroxyl, Ci-Cg-alkoxy, Cx-Cg-alkyl or amino.
  • R * L represents a hydrogen atom or a straight-chain or branched alkyl group with 1-6 carbon atoms.
  • the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, n-hexyl and isohexyl groups are preferred
  • 2 can represent a hydrogen atom or a straight-chain or branched C 1 -C 6 -alkyl group.
  • the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, n-hexyl and isohexyl group are preferred.
  • R2 can also be a straight-chain or branched C3-C6-
  • Alkylene group mean.
  • the allyl, 2-methylallyl, isobutenyl, pentenyl, isopentenyl, hexenyl and isohexenyl group are preferred.
  • R2 can also mean a straight-chain or branched C3-C6 alkynyl group. This means in particular a 2-propynyl, 2-butynyl, 3-butynyl, pentynyl or hexynyl radical.
  • a C3 ⁇ C5-C cloalkyl radical for R3 means a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl radical.
  • R3 and R4 can be the same or different and independently of one another are hydrogen, halogen, such as fluorine, chlorine or bromine, hydroxy, alkyl, such as methyl or ethyl, or alkoxy, such as methoxy or ethoxy,
  • the compounds of general formula I can have one or more
  • REPLACEMENT LEAF have asymmetric carbon atoms.
  • the invention therefore also relates to all optically active and diastereomeric forms and racemic and diastereomeric mixtures.
  • R * j_, 2, R 3 and R4 have the meanings given, are prepared by using a compound of the general formula II,
  • R ⁇ _, R 2 , R3 and R4 have the meanings given, according to a conventional method with a reagent which transfers the thiocarbonyl group, such as, for example, carbon disulfide, thiocarbonyldiimidazole, thiophosgene or thiourea.
  • a reagent which transfers the thiocarbonyl group such as, for example, carbon disulfide, thiocarbonyldiimidazole, thiophosgene or thiourea.
  • R 1, R 2, R 3 and R 4 have the meanings indicated and convert the nitro group into an amino group by a conventional method known to the person skilled in the art.
  • the compounds of general formula III can be prepared by using a compound of general
  • X represents a halogen atom or a sulfonic ester grouping.
  • the compounds of general formula IV can be prepared by using a compound of general formula VI,
  • REPLACEMENT LEAF in which R_, 3 and 4 have the meanings given and Y represents a halogen atom, is subjected to a cyclization reaction.
  • R] _, R3, R4 and Y have the meanings given, is subjected to a reduction using hydrogen boron or diborane.
  • the compounds of the general formula VII can be prepared by using a compound of the general formula VII
  • R, R 3 , R4 and Y have the meanings given, and R5 is hydrogen or an alkyl radical, is subjected to an amidation reaction by methods known to those skilled in the art.
  • the compounds of the general formula VIII can be prepared by using a compound of the general formula VIII
  • Ri has the meanings given and R 5 is hydrogen or an alkyl radical, brings about the reaction in the customary manner.
  • the compounds of the general formula IX are known from the literature or can be prepared by methods known from the literature.
  • REPLACEMENT LEAF are and relate to racemates or optically active compounds.
  • the reactions of the compounds of the general formula II with a reagent transferring a thiocarbonyl group to a compound of the general formula I are carried out by, for example, reacting a compound of the general formula II with carbon disulfide in an aqueous-alcoholic solution in the presence of alkali by a method known to those skilled in the art or by reacting a compound of the general formula II with thiocarbonyldiimidazole in an inert solvent, such as, for example, Dimethylformamide brings to reaction.
  • the compounds of the general formula II are prepared by converting the nitro group into an amino group in a compound of the general formula by a method known to those skilled in the art.
  • the compounds of the general formula IV are reacted with compounds of the general formula V to give compounds of the general formula III by reacting the compounds of the general formula IV with compounds of the general formula V in an inert solvent, such as, for example, dimethylformamide, dimethylacetamide, acetone, methyl ethyl ketone or alcohol at at temperatures between room temperature and reflux temperature of the solvent, tion agent such as sodium carbonate or potassium carbonate to the skilled person by methods known brings preferably between 40 "C and 60 C in the presence of a ⁇ alkaline Kondensa ⁇ to the reaction.
  • an inert solvent such as, for example, dimethylformamide, dimethylacetamide, acetone, methyl ethyl ketone or alcohol
  • the cyclization of a compound of general formula VI to a compound of general formula IV can be carried out by using a compound of general Formula VI in an inert solvent such as dimethyl formamide, dimethylacetamide, acetone, methyl ethyl ketone or alcohol in the presence of an alkaline condensing agent such as sodium carbonate or potassium carbonate to react at temperatures between room temperature and the reflux temperature of the solvent.
  • an inert solvent such as dimethyl formamide, dimethylacetamide, acetone, methyl ethyl ketone or alcohol
  • an alkaline condensing agent such as sodium carbonate or potassium carbonate
  • the cyclization reaction of a compound of the general formula VI to a compound of the general formula IV can also be carried out by heating a compound of the general formula IV in the presence of an alkaline condensing agent, such as, for example, sodium carbonate or potassium carbonate, without the addition of a solvent to temperatures between 100 "C and 200 ⁇ C, preferably between 130 ⁇ C and 170 ° C.
  • an alkaline condensing agent such as, for example, sodium carbonate or potassium carbonate
  • the compounds of the general formula VI are shown in that a compound of the general formula VII with hydrogen boron or diborane in an inert solvent, such as e.g. Tetrahydrofuran, dioxane, diethyl ether or methylene chloride at temperatures between room temperature and reflux temperature of the solvent or by reacting a compound of general formula VI in an inert solvent such as e.g. Subjects methylene chloride reduction with a tetraalkylammonium borohydride.
  • an inert solvent such as e.g. Tetrahydrofuran, dioxane, diethyl ether or methylene chloride
  • B a borane-ammonia complex, borane-tert-butylamine complex, borane-N, N-diethylaniline complex, borane-dimethylamine complex, borane-4-dimethylaminopyridine complex, borane-dimethyl sulfide complex, borane -Dimethyl sulfide complex, borane-N-ethyldiisopropylamine complex, borane-N-ethylmorpholine complex, borane-2,6-lutidine complex, borane-N-methylmorpholine complex, borane-morpholine complex, borane-1,4 -Oxathian complex, borane-N-phenylmorpholine complex, borane-piperazine complex,
  • the compounds of the general formula VII are illustrated by subjecting a compound of the general formula VIII to an amide formation reaction according to the person skilled in the art and methods known from the literature.
  • the compounds of general formula VIII can be prepared by reacting a compound of general formula IX with a compound of general formula X by methods known to those skilled in the art.
  • the invention relates in particular to a new and economical process for the production of

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP91918424A 1990-11-16 1991-10-29 Verfahren zur herstellung von 4,5,6,7-tetrahydro-imidazo-(4,5,ljk) (1,4)-benzodiazepin-2-(1h)-thionen sowie zwischenprodukte Withdrawn EP0557307A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4036552 1990-11-16
DE4036552A DE4036552C1 (pt) 1990-11-16 1990-11-16

Publications (1)

Publication Number Publication Date
EP0557307A1 true EP0557307A1 (de) 1993-09-01

Family

ID=6418388

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91918424A Withdrawn EP0557307A1 (de) 1990-11-16 1991-10-29 Verfahren zur herstellung von 4,5,6,7-tetrahydro-imidazo-(4,5,ljk) (1,4)-benzodiazepin-2-(1h)-thionen sowie zwischenprodukte

Country Status (9)

Country Link
EP (1) EP0557307A1 (pt)
JP (1) JPH06502400A (pt)
AU (1) AU8855991A (pt)
CA (1) CA2096238A1 (pt)
DE (1) DE4036552C1 (pt)
IE (1) IE913979A1 (pt)
IL (1) IL100033A0 (pt)
WO (1) WO1992008706A1 (pt)
ZA (1) ZA919050B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238664A (en) * 1990-07-06 1992-12-23 Janssen Pharmaceutica Nv Substituted tetrahydroimidazo(1,4)benzodiazepin-2-(thi)ones and pharmaceutical anti-viral compositions
WO1993006106A1 (en) * 1991-09-24 1993-04-01 Janssen Pharmaceutica N.V. PROCESS FOR PREPARING ENANTIOMERICALLY PURE IMIDAZO[4,5,1-jk][1,4]-BENZODIAZEPIN-2(1H^_)-THIONES
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8806449D0 (en) * 1988-03-18 1988-04-20 Janssen Pharmaceutica Nv Antiviral hexahydroimiazo(1 4)benzodiazepin-2-ones
IL93136A (en) * 1989-02-23 1995-01-24 Janssen Pharmaceutica Nv History of tetrahydroimidazo [1,4] benzodiazepine-2-thione, their preparation and pharmaceutical preparations containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9208706A1 *

Also Published As

Publication number Publication date
IE913979A1 (en) 1992-05-20
JPH06502400A (ja) 1994-03-17
DE4036552C1 (pt) 1992-02-06
ZA919050B (en) 1992-08-26
CA2096238A1 (en) 1992-05-17
AU8855991A (en) 1992-06-11
IL100033A0 (en) 1992-08-18
WO1992008706A1 (de) 1992-05-29

Similar Documents

Publication Publication Date Title
DE69216251T2 (de) Substituierte aryl- und heteroaryl-phenyloxazolidinone
DE2434911C2 (de) Phenyläthylamin-Derivate und pharmazeutische Zusammensetzungen
DD282686A5 (de) Verfahren zur herstellung eines benzothiazolderivates
EP0287907A1 (de) Pyrazolo[3,4-d]pyrimidine, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
DE1670753A1 (de) Verfahren zur Herstellung von 2-Cycloalkylaminooxazolinen
DE2305092A1 (de) Alpha-aminomethylbenzylalkoholderivate
DE2757680A1 (de) Neue 2-oxo-1-pyrrolidinessigsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2006978B2 (de) N- [H3-Trifluormethyl-phenyl)-propyl-(2)] -glycinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP0557307A1 (de) Verfahren zur herstellung von 4,5,6,7-tetrahydro-imidazo-(4,5,ljk) (1,4)-benzodiazepin-2-(1h)-thionen sowie zwischenprodukte
CH620682A5 (en) Process for the preparation of novel 2,6-disubstituted 2-phenyliminoimidazolidines and their acid addition salts
DE69103535T2 (de) 1-Phenylalkyl-3-Phenylharnstoff-Derivate.
EP0012822B1 (de) Neue 3,4-disubstituierte 2-Phenylimino-imidazolidine, deren Säureadditionssalze, diese enthaltende Arzneimittel und Verfahren zu deren Herstellung
DE2609574C3 (de) 1 -^-Fluor-S-trifluormethylthiophenyD-piperazin, dessen Salze, Verfahren zu dessen Herstellung und Arzneimittel
EP0491243A1 (de) Alkylaminoalkylamin- und -äther- Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2918832A1 (de) 5,6-dihydro-11-alkylen-morphantridin- 6-one
DE2230003A1 (de) Neue nitrosoharnstoffderivate
AT230365B (de) Verfahren zur Herstellung neuer 9-Aminoalkyl-9,10-dihydro-9,10-äthano-(1',2')-anthrazene und deren Salze bzw. quaternären Ammoniumverbindungen
DE2601703C2 (de) 2-(Indenyloxymethyl)morpholin-Derivate
DE1046063B (de) Verfahren zur Herstellung neuer, amoebicid wirkender Acetanilide
DE956306C (de) Verfahren zur Herstellung von neuen Derivaten des Pyrimidins
DE844897C (de) Verfahren zur Herstellung von Diamidinderivaten
DE2742158A1 (de) Herstellung substituierter harnstoffe
DE3710254A1 (de) Antiulcusmittel
DE2253554A1 (de) 2-amino-2-oxazoline und verfahren zu ihrer herstellung
WO1984000032A1 (en) Amino-oxy-(mercapto-alkyl)-benzenes, method for the preparation thereof and pharmaceutical products containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930424

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950503